THE 30-SECOND OVERVIEW
At a glance
Tesamorelin and CJC-1295 are both growth hormone-releasing hormone analogues built to solve the same problem: native GHRH is cleared from circulation within minutes, which makes it impractical to study. Each solves it a different way, and the resulting molecules behave differently enough that comparing them on effect alone misses what actually separates them.
A further complication is that "CJC-1295" refers to two distinct compounds in common usage, and most confusion about it traces back to that.
Native GHRH has two clearance problems
Endogenous GHRH is degraded by dipeptidyl peptidase-4, which cleaves near the N-terminus, and it is cleared renally. Any analogue intended to persist has to address at least one.
Tesamorelin addresses the enzymatic route. It is the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid group attached at the N-terminus, positioned to obstruct DPP-4 access. The peptide itself is unmodified; the protection is a bolt-on.
CJC-1295 addresses both, and by a different strategy. It is GHRH(1-29) with four amino acid substitutions that confer DPP-4 resistance, and, in its original form, a maleimidoproprionic acid linker that binds covalently to circulating serum albumin. Albumin has a half-life measured in weeks, so a molecule tethered to it is carried along.
The two CJC-1295 forms are not interchangeable
This distinction drives most of the confusion in the category.
CJC-1295 with DAC carries the Drug Affinity Complex, the albumin-binding linker. Published pharmacokinetic work reports a half-life in the region of six to eight days, with growth hormone and IGF-1 elevation sustained across that period after a single administration.
CJC-1295 without DAC is the same substituted GHRH(1-29) sequence without the linker. It is more accurately called modified GRF(1-29), and its half-life is roughly 30 minutes. It behaves like sermorelin with added enzymatic resistance, not like the DAC version.
These are different molecules with different pharmacokinetics, and material sold under the shared name may be either. Any protocol or comparison referencing "CJC-1295" without specifying DAC status is ambiguous to the point of being uninterpretable.
Sustained elevation versus pulsatile release
The engineering difference produces a physiological one, and it is the substantive question in this comparison.
Growth hormone is normally released in pulses, with the largest occurring during slow-wave sleep, and the pulsatile pattern is thought to matter to downstream signalling rather than being incidental to it. Receptor desensitisation and the periodicity of gene expression both track the pulse pattern, not just total exposure.
Tesamorelin's once-daily protocol produces elevated release while still leaving the pattern subject to somatostatin's inhibitory cycle. CJC-1295 with DAC, by design, produces sustained elevation across days, described in the literature as a "bleed" of continuous release rather than discrete pulses.
Whether sustained elevation is preferable to pulsatile stimulation is not settled by either compound's data. It is a real open question, and it is the most interesting thing about the comparison. The tesamorelin trials measured a clinical endpoint over 26 weeks; the CJC-1295 work measured pharmacokinetics and hormone levels over much shorter windows. Neither set of studies was designed to answer whether the release pattern changes outcomes.
The clinical records are very different
Tesamorelin has two phase 3 randomised placebo-controlled trials in HIV-associated lipodystrophy, roughly 800 participants combined, an FDA approval as Egrifta, and 52-week extension data including what happens after discontinuation. The protocol was 2mg once daily, subcutaneous.
CJC-1295 was developed by ConjuChem and reached phase 2. Published work established the pharmacokinetics of the DAC form and documented dose-dependent growth hormone and IGF-1 elevation in healthy adults. Development did not continue to phase 3, and no form of CJC-1295 holds approval in any jurisdiction.
The available CJC-1295 studies were short and small relative to the tesamorelin programme, and they measured hormone levels rather than clinical outcomes. That is a normal early-phase design; it simply means there is no outcome dataset to compare against tesamorelin's.
What combination protocols assume
CJC-1295 appears frequently in combination with ipamorelin, and the rationale is mechanistic: a GHRH-receptor agonist and a ghrelin-receptor agonist engage separate pathways, and preclinical work reports additive release when both are stimulated.
That rationale is sound as pharmacology. It is not a trial result. There is no substantial published clinical literature evaluating the combination, so combination protocols are extrapolations from receptor biology rather than studied regimens. The same caveat applies to most peptide stacking.
Tesamorelin was studied as a single agent throughout its trial programme.
What neither compound's data establishes
Both raise growth hormone and IGF-1. Both depend on pituitary capacity, since neither supplies growth hormone directly. Both are supplied lyophilised and neither survives oral administration.
IGF-1 elevation is a pharmacodynamic marker, not an outcome. The tesamorelin trials measured visceral adipose tissue directly rather than inferring it, which is the more informative approach and also the more expensive one. It is the step the CJC-1295 literature never took.
Neither compound has published research supporting use outside a controlled setting. Both are supplied for research use only.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Teichman, S. L., Neale, A., Lawrence, B., et al. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805.
2. Falutz, J., Mamputu, J. C., Potvin, D., et al. (2010). Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter trials. Journal of Clinical Endocrinology and Metabolism, 95(9), 4291-4304.
3. Jetté, L., Léger, R., Thibaudeau, K., et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology, 146(7), 3052-3058.
4. Egrifta (tesamorelin for injection) prescribing information. US Food and Drug Administration.
